- Home
- NIO vs MDGL Comparison
NIO vs MDGL Comparison
Compare NIO & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NIO | MDGL |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 12.5B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | NIO | MDGL |
|---|---|---|
| Price | $4.99 | $556.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 14 |
| Target Price | $6.73 | ★ $553.08 |
| AVG Volume (30 Days) | ★ 51.9M | 317.0K |
| Earning Date | 11-25-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,189,444,895.00 | $740,640,000.00 |
| Revenue This Year | $35.91 | $436.04 |
| Revenue Next Year | $46.42 | $53.17 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 14.90 | ★ 864.21 |
| 52 Week Low | $3.02 | $265.00 |
| 52 Week High | $8.02 | $605.00 |
Technical Indicators
Market Signals| Indicator | NIO | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 33.13 | 54.32 |
| Support Level | $4.90 | $546.20 |
| Resistance Level | $5.26 | $589.67 |
| Average True Range (ATR) | 0.21 | 20.61 |
| MACD | 0.03 | -6.67 |
| Stochastic Oscillator | 26.53 | 20.49 |
Price Performance
Historical ComparisonAbout NIO NIO Inc. American depositary shares each representing one ordinary share
Nio is a leading electric vehicle maker, targeting the premium segment. Founded in November 2014, Nio designs, develops, jointly manufactures, and sells premium smart electric vehicles. The company differentiates itself through continuous technological breakthroughs and innovations such as battery swapping and autonomous driving technologies. Nio launched its first model, its ES8 seven-seater electric SUV, in December 2017, and began deliveries in June 2018. Its current model portfolio includes midsize to large sedans and SUVs. It sold around 222,000 EVs in 2024, accounting for about 2% of the China passenger new energy vehicle market.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.